This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.本發明係有關一種新穎化合物，其係轉染期間重排(RET)激酶之抑制劑，並有關含其之醫藥組成物、其製法、及其於醫療上之用途，其可單獨或組合用於恢復正常胃腸敏感性、蠕動性與/或分泌與/或腹部病變或疾病，及/或用於與RET功能失常相關或可能因調控RET活性而得到醫療效益之疾病之相關處理法，該等疾病包括(但不限於)：所有種類之腸道激躁症(IBS)，包括腹瀉型、便秘型或交替糞便型；功能性脹氣、功能性便秘、功能性腹瀉、不明確之功能性腸道病變、功能性腹部疼痛症候群、慢性特發性便秘、功能性食道病變、功能性胃與十二指腸病變、功能性肛門直腸疼痛、炎性腸道疾病；增生性疾病，如：非小細胞肺癌、肝細胞癌瘤、結腸直腸癌、甲狀腺髓樣癌、濾泡性甲狀腺癌、甲狀腺未分化癌、乳突性甲狀腺癌、腦腫瘤、腹膜腔癌、實體腫瘤、其他肺癌、頭與頸癌、膠質瘤、神經母細胞瘤、馮希柏-林島氏症候群(Von Hippel-Lindau Syndrome)、及腎臟腫瘤、乳房
